Kornimate/medical-research-clean huggingface dataset:
impact of chair seat height on the 1-minute sit to stand test performance in chronic obstructive pulmonary disease

Conditions: COPD; Chronic Obstructive Pulmonary Disease

Summary: the 1-minute sit to stand (1-min sts) test is a standardized test which is used to examine exercise capacity in patients with chronic obstructive pulmonary disease (copd). the chair seat height used is standardized to 46-48 cm. using a standard seat height for all patients - irrespective of their body height - may lead to invalid estimates of functional exercise capacity. the objective of this study is to assess whether there is a difference in repetitions during the 1-min sts test if the seat height is adjusted to 90° knee joint angle or the standard height chair of 46 cm is used.

in a single-center, randomized crossover study, the investigators aim to elucidate whether there is a difference in repetitions during the 1-min sts test if the seat height is adjusted to 90° knee joint angle or the standard height chair of 46 cm is used. patients with copd referred for pulmonary rehabilitation will be invited to perform one standardised- (chair seat height 46cm) and one individualized (chair seat height adapted to 90° knee flexion) 1-min sts test on two different days in random order. the tests will be performed after patients are familiarised with the 1-min sts testing procedure and learning effects can be excluded.

Eligibility criteria:
inclusion criteria: * patients with diagnosed copd according to a forced expiratory volume in 1s (fev1) / forced vital capacity (fvc) ratio below the lower limit of normal exclusion criteria: * patients who are not able to bend their knees while sitting on a standard chair (i.e., knee flexion less than 90°) * patients who are not able to understand the instructions of the 1-min sts test, either of language or cognitive reasons * patients who are unable to perform the sts test due to functional disability (i.e., being not able to rise from a chair without hand support), previous surgery, or pain according to the judgement of the responsible physician. * patients who did not sign the informed consent form

Keywords: 1-minute sit to stand test chair seat height
verbal and visual information techniques on anxiety in third molar surgery

Conditions: Impacted Third Molar Tooth

Summary: the aim of this study was to evaluate preoperative anxiety levels using dental anxiety scale (das) and the spielberger state-trait anxiety inventory (stai).

this study will based on a prospective, observational investigation of two different patient education techniques about the effect of third molar removal on patients' anxiety level. a total of 240 patients will be divided into two groups. information about operation procedures and a recovery will be given verbally in group 1 and information about operation procedures and recovery will be given in group 2. anxiety levels were assessed by using das and (stai).paired t-test or wilcoxon test will be used for intra-group comparison of anxiety levels.

Eligibility criteria:
inclusion criteria: * impacted third molar (bone and mucosa retention, mesioangular position) * patients with any chronic disease and allergy exclusion criteria: * pericoronitis * patients with visual impairment * patients with psychological disorders * smoking * pregnancy or lactation

Keywords: video anxiety
early embryo cleavage and multiple pregnancies after icsi

Conditions: Infertility

Summary: to observe whether number of early cleavage embryos can be a predictor for multiple pregnancies after icsi.

a total of 193 infertile couples, attending the art unit, international islamic center for population studies and research (iicpsr), -al- azhar university in the period from december 2010 to september 2012, were included in this study. the controlled ovarian hyperstimulation protocol was performed according to a long gnrh agonist protocol starting in the midluteal phase (day 21) of the preceding cycle. embryos were assessed at 25 - 27 hr after icsi for early cleavage. embryos which reached the two cell stage at this interval were classified as early cleavage (ec) embryos, and the remaining as non early cleavage (nec) embryos. embryos were assessed again at 64 - 68 hours post-icsi for day-three embryo morphology. day 3 embryo transfer was done. the best two or three embryos, according to day 3 embryo morphology were transferred. the patients were subdivided into two subgroups; one will transfer early cleavage embryos (ec) and the other will transfer non early cleavage embryo (nec).

Eligibility criteria:
inclusion criteria: * bmi \>25 - 30 kg/m2 * have two ovaries * regular cycles * first icsi cycle * long midluteal gnrh protocol. exclusion criteria: * uterine factor as a cause of female factor infertility * pelvic masses or diseases (e.g: endometriosis, fibroids, hydrosalpnix, ...) * history of medical disorders (e.g: hypertension, d.m, thyroid dysfunction, liver diseases, renal diseases,...) * azoospermia as a cause of male factor infertility
does intensive acid suppression reduce esophageal inflammation and recurrent barrett's esophagus following ablation?

Conditions: Inflammation; Barrett's Esophagus

Summary: the investigators hypothesize that intensive acid suppression with a long acting high potency proton pump inhibitor (ppi) drug dexlansoprazole will lead to a greater decrease in levels of inflammatory mediators (compared to conventional ppis) in the esophagus, which could potentially lead to decreased recurrence of intestinal metaplasia following endoscopic ablation.

patients who achieve complete remission of intestinal metaplasia following ablation will be randomized (using concealed allocation, like the flip of a coin) to either intensive acid suppression with dexlansoprazole 60-90 mg/day or to symptom guided acid suppression with escalating doses of omeprazole (20-60 mg/day) for 6 months. control of reflux will be assessed using 24 hour ambulatory ph monitoring. the need to escalate drug dosage at the 3 month visit will be determined by presence of excessive acid exposure on ambulatory ph monitoring. biopsies of esophageal tissue will be obtained at baseline, then at 3 months and 6 months following randomization to measure changes in inflammatory biomarkers.

Eligibility criteria:
patients who have undergone ablation for barrett's esophagus (be) and high grade dysplasia (hgd) or low grade dysplasia (lgd) with photodynamic therapy (pdt)/radiofrequency ablation and endoscopic mucosal resection who have no endoscopic and histologic evidence of specialized intestinal metaplasia on biopsies from the esophagus on two successive endoscopies post ablation will be offered enrollment in the study. inclusion criteria: 1. absence of intestinal metaplasia on endoscopy (under narrow band imaging) and on histology (from biopsies taken from gastroesophageal junction and distal esophagus) on two successive surveillance endoscopies. 2. able to consent to study 3. males and females age 18-90 4. life expectancy of 5 years or greater. exclusion criteria: 1. pregnancy 2. inability to consent for the procedure 3. anticoagulation therapy precluding performance of ambulatory ph monitoring and/or biopsies 4. intolerance to proton pump inhibitors 5. elevation in alanine aminotransferase (alt), aspartate aminotransferase (ast), (liver enzymes), bilirubin or alkaline phosphatase more than five times the upper limit of normal.

Keywords: barrett's esophagus radiofrequency ablation patients post-radiofrequency ablation for barrett's esophagus.
duration of immune response to influenza vaccination in patients with ra

Conditions: Rheumatoid Arthritis

Summary: the main objective is to evaluate the strength and duration of immune response after influenza vaccination in patients with rheumatoid arthritis (ra) receiving treatment with biological agents as compared to a group healthy controls who do not have ra. influenza vaccine titers will be drawn 3 times: at baseline(prior to vaccination), 4-6 weeks post vaccination, and 5-6 months post vaccination. influenza vaccination will be done at the baseline visit after the baseline blood draw.

aims: * evaluate the strength and duration of immune response after influenza vaccination in patients with rheumatoid arthritis (ra) receiving treatment with biological agents. * evaluate for predictors of immune response such as age, gender, disease duration, type of the biological agent(s) used, duration of the treatment, and type of treatment in the past. * assess the efficacy of vaccine response in this population by recording proportion of patients who contracted influenza illness despite vaccination. the result of the study may provide more information regarding which situations inadequate immune response by strength or duration would most likely to be expected. this may help lay some groundwork for future studies looking at the use of booster vaccinations in this population

Eligibility criteria:
inclusion criteria: inclusion criteria (ra patients) * patients with ra receiving treatment with an anti-t cell or anti-tnf biological agent * age 40-75 inclusion criteria (healthy controls): * age 40-75 exclusion criteria: exclusion criteria (ra patients) * known hypersensitivity/allergy influenza vaccine * chronic debilitating conditions (such as end-stage chronic obstructive pulmonary disease (copd), congestive heart failure (chf), liver disease, chronic kidney disease (ckd) ) * active malignancy at time of vaccination * pregnancy and lactation * known hiv * active infection at time of vaccination * recent acute illness (within 1 month prior to vaccination) exclusion criteria(healthy controls): * known autoimmune conditions * chronic use of immunosuppressant treatments * known hypersensitivity/allergy influenza vaccine * chronic debilitating conditions (such as end-stage copd, chf, liver disease, ckd) * active malignancy at time of vaccination * pregnancy and lactation * known hiv * active infection at time of vaccination * recent acute illness (within 1 month prior to vaccination)
sentinel node mapping in women with cervical and endometrial cancer

Conditions: Uterine Cervical Neoplasms; Uterine Neoplasms

Summary: this study aims to evaluate the effect of sln mapping on the incidence and severity of lymphedema in women with early stage cervical and endometrial cancer.


Eligibility criteria:
inclusion criteria: * study ia: cervical carcinoma, figo stage ib1, cervical tumour size \< 2 cm * study ib: endometrial adenocarcinoma, presumed figo stage i, low- and intermediate risk: type 1 grade 1 + 2, \> 50% myometrial invasion exclusion criteria: * prior pl * known allergy towards icg and/or iodine (icg contains 5% sodium iodine) * women included in other studies affecting outcome-measures of the present study

Keywords: robotic surgery procedure indocyanine green sentinel lymph node mapping
effects of physiotherapy in individuals with persistent symptoms following concussion

Conditions: Sport-related Concussion

Summary: the purpose of this study is to determine the effects of a combined physiotherapy treatment (including vestibular rehabilitation and treatment for the cervical spine) in youth and young adults with ongoing symptoms of dizziness, neck pain and headaches following a sport-related concussion.


Eligibility criteria:
inclusion criteria: * diagnosis of sport-related concussion as per the third international consensus guidelines * persistent symptoms (greater than 10 days) of dizziness, unsteadiness, neck pain and/or headaches reported on the sport concussion assessment tool 2 (scat2) * clinical examination findings suggesting vestibular and/or cervical spine involvement exclusion criteria: * fracture, other neurological conditions, musculoskeletal injuries (other than the cervical spine) that restrict activity and medications that affect neural adaptation

Keywords: sport-related concussion dizziness neck pain headaches physiotherapy treatment
efficacy study of pneumococcal vaccination in crohn's disease

Conditions: Crohn's Disease

Summary: a growing number of patients with crohn's disease are treated with immunosuppressive agents, such as anti-tumor necrosis factor blockers and immunomodulators. several recent studies have indicated that immunosuppressive treatment may impair the immunological response to pneumococcal vaccination in patients with inflammatory bowel disease (crohn's disease and ulcerative colitis). one of weaknesses in the previous studies did not focus on specific disease, such as crohn's disease. in addition, predictive factors affecting impaired response following pneumococcal vaccination have not clearly evaluated in patients with crohn's disease. in this study, patients with crohn's disease will be assessed for serological response to pneumococcal vaccination. further, potential predictive factors that impact on vaccination outcomes and adverse events related to vaccination will be evaluated.


Eligibility criteria:
inclusion criteria: * patients over the age of 18 * informed consent * patients who had a definitive diagnosis of crohn's disease for more than 6 months (documented by the standard clinical, radiographic, endoscopic, and histopathologic criteria) exclusion criteria: * hypersensitivity to any component of the pneumococcal vaccine * known allergy to pneumococcal vaccination * patients who treated with glucocorticoids (prednisolone \> 20 mg/day equivalent for 2 weeks or more, and within 3 months of stopping * patients who inoculate another vaccine in the past 4 weeks * significant protein calorie malnutrition * current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, infectious, neurologic or cerebral disease * any condition which, in the opinion of the investigator, places the patient at unacceptable risk if he/she were to participate in the study

Keywords: crohn's disease pneumococcal vaccination
phase iii study of da-3031(peg-g-csf) in chemotherapy-induced neutropenia

Conditions: Chemotherapy Induced Neutropenia

Summary: this study is to determine whether once-per-cycle da-3031(peg-g-csf) is not inferior to daily g-csf in chemotherapy-induced neutropenia.

eligible subjects are randomly assigned to receive once-per-cycle da-3031(peg-g-csf) or daily g-csf(up to 10 days). this study is conducted for 6 cycles of chemotherapy, that each cycle is repeated every 21 days.

Eligibility criteria:
inclusion criteria: 1. age : ≥18, ≤70 2. diagnosis of stage ii, iii or iv breast cancer 3. anc≥1,500/mm3, platelet≥100,000/mm3, ecog : 0 or 1 4. creatinine \< 1.5 x uln 5. total bilirubin/ast/alt \< 1.5 x uln, alp \< 2.5 x uln 6. have given a written, informed consent exclusion criteria: 1. prior chemotherapy 2. prior bone marrow or stem cell transplantation 3. other malignancy history within 5 years 4. prior exposure to pegfilgrastim or filgrastim or other colony-stimulating factors 5. received any other investigational drugs within 30 days of informed consent date 6. radiation therapy within 4 weeks of informed consent date 7. infective symptom before chemotherapy into this study 8. received systemic antibiotics within 72 hours of randomization into this study. 9. hiv positive 10. pregnant or lactating women

Keywords: peg-g-csf
chest imaging, breath, and biomarkers in a screening trial

Conditions: Lung Cancer

Summary: the investigators would like to see if lung cancer screening with chest x-rays,computer aided detection (cad)and a lose dose ct scan can detect lung cancer in early stages when it is more responsive to treatment. the investigators would also like to see if early detection will reduce the incidence of symptomatic advanced lung cancer compared to no screening in former and current smokers with or without a family history of lung cancer who are 40-75 years old.

the fight against lung cancer is waged on three major fronts: prevention, detection and treatment. our goal is to determine if chest x-rays,computer aided detection (cad)and a ct scan can detect disease earlier when treatment is more effective. if we improve the detection of disease, we will see if screening reduces the incidence of symptomatic advanced lung cancer relative to no screening in people at high risk to develop lung cancer.

Eligibility criteria:
inclusion criteria: * ages 40-75 years * if ages 40-59, then one of the following criteria needs to be met: * current or ex-smoker with \>25 pack years and a family history of lung cancer(parent or sibling) or * current or ex-smoker with \> 25 pack years and copd or * current or ex-smoker with a \> 35 pack year history * if ages 60-75, then one of the following additional criteria needs to be met: * current or ex-smoker with \>25 pack years and a family history of lung cancer (parent or sibling) or * current or ex-smoker with \>25 pack years and copd or * current or ex-smoker with a \>30 pack year history * subject is able to return to cleveland clinic for annual follow-up screening * subject is willing to sign a medical release form exclusion criteria: * current health requires oxygen * have had a chest x-ray or ct of the chest within the last 6 months * previous pneumonectomy * lobectomy of the lung within the last 5 years * diagnosed malignancy within the last 5 years, excluding non-melanoma skin cancer, carcinoma in situ of the cervix and localized prostate cancer * a medical condition that would prevent treatment for lung cancer * within the last 6 weeks, one of the following has occured: * a new cough or chronic cough that has gotten worse * either new shortness of breath, or any worsening of shortness of breath * a cough producing blood * constant chest pain * respiratory infection, pneumonia, or cold * unintentional and unexplained weight loss greater than 5% of total body weight

Keywords: lung cancer chest x-ray ct scan computer aided detection (cad) screening smokers
canadian community utilization of stroke prevention study - emergency department

Conditions: Atrial Fibrillation; Stroke

Summary: atrial fibrillation (af) is a common heart condition, and increases the risk of stroke by six times. there are several medications (blood thinners) that can prevent strokes in af patients. many af patients present to the emergency department, but about half of af patients leave without prescription of a blood thinner. the study aims to evaluate if adding options like giving a patient education kit, encouraging emergency room physicians to prescribe a blood thinner and providing a specialized af clinic to patients will increase the number patients receiving blood thinners to prevent strokes.

this is a knowledge translation study will occur in three consecutive phases: phase 1 is a retrospective chart review of all patients who presented to the emergency department (ed) with ecg documented af during 1 year prior to study commencement. the main purpose of phase 1 is to determine if oral anticoagulants (oacs) were prescribed for eligible af patients at ed discharge. in phase 2 a low-intensity intervention will be applied in the ed during 6 months, involving physician education, distribution of an af patient education package, short-term oac prescription, and a follow-up letter to the patient's family physician. after a one month transition phase, a high intensity intervention will be applied during 6 months in phase 3. phase 3 incorporates the phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community af clinic run by a nurse/pharmacist who is supervised by a specialist in af.

Eligibility criteria:
inclusion criteria: * patients who present to the emergency department with electrocardiographically documented atrial fibrillation on a 12 lead ecg exclusion criteria: * prosthetic or mechanical mitral or aortic valve * known rheumatic heart disease * unable to provide informed consent * will be admitted to hospital * life expectancy of \< 6 months * metastatic malignancy

Keywords: oral anticoagulant knowledge translation emergency department
the effect of bowel preparation training given to patients undergoing colonoscopy

Conditions: Colonoscopy

Summary: this study was planned to examine the effect of bowel preparation training and monitoring given to patients planned to undergo colonoscopy on the level of anxiety, compliance with bowel preparation and bowel cleansing. the research sample was collected at the sultan ii. university of health sciences affiliated to the istanbul provincial health directorate between december 2022 and august 2023. 34 intervention and 34 control groups will be randomly selected from outpatients who apply to the colonoscopy unit of abdülhamid han training and research hospital and meet the inclusion criteria. in this study, it is aimed to increase the effect of bowel preparation training, supported by nurses in the clinic and via instant messaging/calling or communication application, on patients' anxiety level, level of compliance with bowel preparation, and bowel cleansing in patients scheduled for colonoscopy.


Eligibility criteria:
inclusion criteria: * colonoscopy is planned * understands turkish, can read and write, * patients who volunteer to participate in the research. exclusion criteria: * patients who do not attend planned training and do not receive telephone counseling

Keywords: colonoscopy bowel preparation anxiety
the effects of glucomannan on weight loss

Conditions: Obesity

Summary: the purpose of this study is to determine if the herb, glucomannan, is an effective non-pharmacological appetite suppressant for overweight or class i obese patients. the study design will not include any other lifestyle changes which enhance weight loss in order to completely isolate the effects of glucomannan as a non-pharmacological appetite suppressant.


Eligibility criteria:
inclusion criteria:subjects will be recruited based upon the category of them wanting to lose 50 pounds. subjects must be able to swallow the capsule whole with water. exclusion criteria: 1. self-reported use of prescription medication other than hormonal birth control (such as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.) 2. pregnancy 3. age younger than 21 or older than 60 years of age. 4. screening for hypertension during the first laboratory visit that reveals a systole greater than 120 and a diastole greater than 90. 5. bmi calculations based upon height and weight measurements at the first laboratory visit that reveal a bmi less than 25 or greater than 35. 6. self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia.

Keywords: obesity overweight glucomannan